Onderneming HedgePath Pharmaceuticals Inc
Aandelen
US42278K1025
Biotechnologie & Medisch Onderzoek
Vakgebied
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Frank O'Donnell
CEO | Chief Executive Officer | 74 | 13-12-22 |
James McNulty
DFI | Director of Finance/CFO | 73 | 13-12-22 |
Amy M. McCord
LAW | General Counsel | - | 01-01-19 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Frank O'Donnell
CEO | Chief Executive Officer | 74 | 13-12-22 |
Samuel Sears
BRD | Director/Board Member | 80 | 02-08-13 |
Ronald Osman
BRD | Director/Board Member | 78 | 23-08-23 |
Niraj Vasisht
BRD | Director/Board Member | 61 | 13-12-22 |
Michelle Yanez
BRD | Director/Board Member | 52 | 13-12-22 |
Michael Jerman
BRD | Director/Board Member | 40 | 24-05-23 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 172 023 545 | 71 400 692 ( 41,51 %) | 0 | 41,51 % |
Bedrijfsgegevens
Inhibitor Therapeutics, Inc.
449 South 12th Street Unit 1705
33602, Tampa
+813 864 2562
http://www.inhibitortx.comSector
Vaira. 1 jan. | Kapi. | |
---|---|---|
+17,96% | 44,96 mld. | |
+1,17% | 42,65 mld. | |
+48,77% | 41,85 mld. | |
-4,27% | 29,04 mld. | |
+11,42% | 26,08 mld. | |
-21,39% | 19,03 mld. | |
+4,86% | 12,75 mld. | |
+27,29% | 12,06 mld. | |
-3,50% | 11,75 mld. |